Copyright © Inderes 2011 - present. All rights reserved.
  • Seneste
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Udbyttekalender
    • Research
    • Artikler
    • Transskriptioner
    • AGM Invitations
    • IPOs
  • InderesTV
  • Forum
  • Discovery
  • Om os
    • Fulgte selskaber
    • Team

Du bruger tilsyneladende en bredere skærm. Vil du gerne give denne side en bredere visningsoplevelse?

Ascelia Pharma – Presentation of Half-Year Report 2023

Af HC Andersen Capital
Ascelia Pharma

Meet and ask questions to CEO Magnus Corfitzen from Ascelia Pharma – Wednesday 23 August at 10.00 CEST.

It’s been a busy first half-year for Ascelia Pharma and besides the financials CEO Magnus Corfitzen will run through the major highlights and what to expect in the second half of 2023.

Ascelia Pharma is a Swedish biotech company that focuses on orphan oncology treatments. They develop and commercialize novel drugs that address unmet medical needs and have a clear development and market pathway. Currently, Ascelia Pharma has two pipeline products, namely Orviglance and Oncoral. Orviglance is a novel contrast agent for MR-Imaging developed to improve the detection and visualization of focal liver lesions (Including liver metastases – and primary tumors) in patients with reduced kidney function. Oncoral is a phase 2 study with an estimated completion date in 2024. Oncoral is a daily tablet with an established potent anti-tumor effect – even in difficult to treat cancers with the potential to offer better patient outcomes with improved safety following a daily tablet treatment compared to intravenous high-dose infusions at the hospital.

Disclaimer: HC Andersen Capital receives payment from Ascelia Pharma for a DigitalIR/Corporate Visibility agreement. Claus Thestrup 11:00 – 04-07-2023.

Seneste videoer

Nederman Holding, Audiocast, Q1'26
17.04.2026, 10.00 Nederman Holding
GreenMobility - Presentation of Q1 2026 Trading Statement
17.04.2026, 10.00 GreenMobility
HCA Morgenbørs 17/04 - Afventende marked med en neutral til svag positiv retning
17.04.2026, 09.31 Novo Nordisk
B&O - CEO-interview i forbindelse med Q3 2025/26 handelsopdateringen
16.04.2026, 15.47 Bang & Olufsen
Luotea: A turnaround case with strong cash flow
16.04.2026, 09.52 Luotea
Vis alle videoer
Find os på de sociale medier
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Vores team
  • Karriere
  • Inderes som en investering
  • Tjenester for børsnoterede virksomheder
Vores platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.